NIH grant to convert a potent IV
therapy for refractory wounds into
a topical formulation
Phoenicia has received a new small business grant from the National Institutes of Health for studies to convert an intravenous therapy which healed refractory, disabling leg ulcers in hemolytic anemias, sickle cell disease and β-thalassemia, into a topical preparation which can be used readily by patients world-wide. While the intravenous treatment was being tested to reduce blood abnormalities, debilitating leg ulcers incidentally healed well before effects on the blood. In a new trial directed to leg ulcers, refractory leg ulcers healed with the IV treatment in patients from the US, Italy, Canada, Brazil, and the Middle East .
This route of administration, however, requires costly supplies and pumps to administer. Phoenicia is collaborating with pharmaceutical companies in California and Taiwan to test new formulations in a specialized model simulating human wound healing, developed by Dr. Vincent Falanga, Vice-Chair of Research in Dermatology, at Boston University School of Medicine and his expert team, with support from the National Institutes of Health.